0:00
13:39
Normally used as a glucose-lowering agent in the treatment of type 2 diabetes, SGLT2 inhibitors have been found to have beneficial effects in patients with heart failure and kidney disease. Jo Cheah finds out more from cardiologist John Atherton.
Mais episódios de "Australian Prescriber Podcast"
Não percas um episódio de “Australian Prescriber Podcast” e subscrevê-lo na aplicação GetPodcast.